Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.

Saved in:
Bibliographic Details
Title: Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.
Authors: Pusztai L; Breast Medical Oncology, Yale Cancer Center, Yale School of Medicine, 333 Cedar Steet, PO Box 208032, New Haven, CT 06510, USA. Electronic address: lajos.pusztai@yale.edu., Yau C; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA., Wolf DM; Department of Laboratory Medicine, University of California, San Francisco, CA 94143, USA., Han HS; Medical Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA., Du L; Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Wallace AM; Comprehensive Breast Health Center, University of California San Diego, La Jolla, CA 92037, USA., String-Reasor E; Department of Hematology & Oncology, University of Alabama at Birmingham, Birmingham, AL 35233, USA., Boughey JC; Department of Surgery, Mayo Clinic, Rochester, MN 55905, USA., Chien AJ; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA., Elias AD; Department of Internal Medicine, University of Colorado, Aurora, CO 80045, USA., Beckwith H; Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA., Nanda R; Department of Medicine, University of Chicago, Chicago, IL 60637, USA., Albain KS; Hematology/Oncology, Loyola University Chicago Stritch School of Medicine, Chicago, IL 60153, USA., Clark AS; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA., Kemmer K; Knight Cancer Institute, Oregon Health & Sciences University, Portland, OR 97239, USA., Kalinsky K; Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA., Isaacs C; Lombardi Comprehensive Care Center, Georgetown University, Washington, DC 20007, USA., Thomas A; Medical Oncology and Hematology, Wake Forest University, Winston-Salem, NC 27157, USA., Shatsky R; Comprehensive Breast Health Center, University of California San Diego, La Jolla, CA 92037, USA., Helsten TL; Moores Cancer Center, University of California San Diego, La Jolla, CA 92037, USA., Forero-Torres A; Department of Hematology & Oncology, University of Alabama at Birmingham, Birmingham, AL 35233, USA., Liu MC; Department of Surgery, Mayo Clinic, Rochester, MN 55905, USA., Brown-Swigart L; Department of Laboratory Medicine, University of California, San Francisco, CA 94143, USA., Petricoin EF; Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA 20110, USA., Wulfkuhle JD; Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA 20110, USA., Asare SM; Quantum Leap Healthcare Collaborative, San Francisco, CA 94118, USA., Wilson A; Quantum Leap Healthcare Collaborative, San Francisco, CA 94118, USA., Singhrao R; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA., Sit L; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA., Hirst GL; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA., Berry S; Berry Consultants, LLC, Austin, TX 78746, USA., Sanil A; Berry Consultants, LLC, Austin, TX 78746, USA., Asare AL; Quantum Leap Healthcare Collaborative, San Francisco, CA 94118, USA., Matthews JB; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA., Perlmutter J; Gemini Group, Ann Arbor, MI 48107, USA., Melisko M; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA., Rugo HS; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA., Schwab RB; Moores Cancer Center, University of California San Diego, La Jolla, CA 92037, USA., Symmans WF; Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Yee D; Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA., Van't Veer LJ; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA., Hylton NM; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA., DeMichele AM; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA., Berry DA; Berry Consultants, LLC, Austin, TX 78746, USA., Esserman LJ; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA.
Source: Cancer cell [Cancer Cell] 2021 Jul 12; Vol. 39 (7), pp. 989-998.e5. Date of Electronic Publication: 2021 Jun 17.
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Cell Press Country of Publication: United States NLM ID: 101130617 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-3686 (Electronic) Linking ISSN: 15356108 NLM ISO Abbreviation: Cancer Cell Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1878-3686
DOI:10.1016/j.ccell.2021.05.009